The Economic Impact of AI Adoption in Healthcare: Estimating National Cost Savings, Productivity Gains, and Long-Term Health Outcomes
DOI:
https://doi.org/10.63282/3050-9262.IJAIDSML-V7I3P101Keywords:
Artificial Intelligence, Healthcare Economics, Cost-Effectiveness, National Health Expenditure, Workforce Productivity, Health Outcomes, Digital HealthAbstract
Artificial intelligence (AI) is increasingly being adopted across healthcare systems to improve diagnostic accuracy, streamline administrative processes, strengthen clinical decision-making, and support preventive care. However, its national economic implications remain insufficiently understood, particularly regarding healthcare cost savings, workforce productivity, and long-term population-health outcomes. This study develops an evidence-informed national economic modelling framework to estimate the potential impact of AI adoption across key healthcare functions, including diagnostic imaging, automated screening, clinical decision support, predictive risk management, telehealth, and administrative automation. The framework compares current healthcare delivery with low-, moderate-, and high-adoption AI scenarios over a ten-year period. Economic outcomes include direct medical cost savings, reduced avoidable hospitalizations, improved diagnostic efficiency, clinician and administrative time savings, increased service capacity, and long-term health benefits measured through avoided complications and quality-adjusted life years. The analysis also incorporates implementation, maintenance, workforce-training, data-infrastructure, and governance costs to estimate net economic value. The study argues that AI can generate substantial national value when deployed in high-volume, high-cost, and prevention-oriented services. Nevertheless, financial benefits depend on interoperable health-data systems, clinical integration, algorithmic accuracy, human oversight, equity safeguards, and continuous performance monitoring. The proposed framework offers policymakers a practical basis for prioritizing responsible AI investments that improve both healthcare efficiency and long-term patient outcomes.
References
[1] Gold, M. R. (Ed.). (1996). Cost-effectiveness in health and medicine. Oxford university press.
[2] Hamet, P., & Tremblay, J. (2017). Artificial intelligence in medicine. metabolism, 69, S36-S40.
[3] Wolff, J., Pauling, J., Keck, A., & Baumbach, J. (2020). Systematic review of economic impact studies of artificial intelligence in health care. Journal of Medical Internet Research, 22(2), e16866.
[4] Vithlani, J., Hawksworth, C., Elvidge, J., Ayiku, L., & Dawoud, D. (2023). Economic evaluations of artificial intelligence-based healthcare interventions: a systematic literature review of best practices in their conduct and reporting. Frontiers in pharmacology, 14, 1220950.
[5] von Wedel, P., & Hagist, C. (2020). Economic value of data and analytics for health care providers: hermeneutic systematic literature review. Journal of medical Internet research, 22(11), e23315.
[6] Al Meslamani, A. Z. (2023). Beyond implementation: the long-term economic impact of AI in healthcare. Journal of medical economics, 26(1), 1566-1569.
[7] El Arab, R. A., & Al Moosa, O. A. (2025). Systematic review of cost effectiveness and budget impact of artificial intelligence in healthcare. NPJ Digital Medicine, 8(1), 548.
[8] Wu, H., Jin, K., Yip, C. C., Koh, V., & Ye, J. (2024). A systematic review of economic evaluation of artificial intelligence-based screening for eye diseases: From possibility to reality. Survey of ophthalmology, 69(4), 499-507.
[9] Gomez Rossi, J., Rojas-Perilla, N., Krois, J., & Schwendicke, F. (2022). Cost-effectiveness of artificial intelligence as a decision-support system applied to the detection and grading of melanoma, dental caries, and diabetic retinopathy. JAMA Network Open, 5(3), e220269.
[10] Xie, Y., Nguyen, Q. D., Hamzah, H., Lim, G., Bellemo, V., Gunasekeran, D. V., ... & Ting, D. S. (2020). Artificial intelligence for teleophthalmology-based diabetic retinopathy screening in a national programme: an economic analysis modelling study. The Lancet Digital Health, 2(5), e240-e249.
[11] Hill, N. R., Sandler, B., Mokgokong, R., Lister, S., Ward, T., Boyce, R., ... & Gordon, J. (2020). Cost-effectiveness of targeted screening for the identification of patients with atrial fibrillation: evaluation of a machine learning risk prediction algorithm. Journal of medical economics, 23(4), 386-393.
[12] Wolf, R. M., Channa, R., Abramoff, M. D., & Lehmann, H. P. (2020). Cost-effectiveness of autonomous point-of-care diabetic retinopathy screening for pediatric patients with diabetes. JAMA ophthalmology, 138(10), 1063-1069.
[13] Mital, S., & Nguyen, H. V. (2022). Cost-effectiveness of using artificial intelligence versus polygenic risk score to guide breast cancer screening. BMC cancer, 22(1), 501.
[14] Ziegelmayer, S., Graf, M., Makowski, M., Gawlitza, J., & Gassert, F. (2022). Cost-effectiveness of artificial intelligence support in computed tomography-based lung cancer screening. Cancers, 14(7), 1729.
[15] Vargas-Palacios, A., Sharma, N., & Sagoo, G. S. (2023). Cost-effectiveness requirements for implementing artificial intelligence technology in the Women’s UK Breast Cancer Screening service. Nature Communications, 14(1), 6110.
[16] de Vos, J., Visser, L. A., de Beer, A. A., Fornasa, M., Thoral, P. J., Elbers, P. W., & Cinà, G. (2022). The potential cost-effectiveness of a machine learning tool that can prevent untimely intensive care unit discharge. Value in Health, 25(3), 359-367.
[17] Rajkomar, A., Dean, J., & Kohane, I. (2019). Machine learning in medicine. New England Journal of Medicine, 380(14), 1347-1358.
[18] Topol, E. J. (2019). High-performance medicine: the convergence of human and artificial intelligence. Nature medicine, 25(1), 44-56.
[19] Obermeyer, Z., & Emanuel, E. J. (2016). Predicting the future—big data, machine learning, and clinical medicine. The New England journal of medicine, 375(13), 1216.
[20] Davenport, T., & Kalakota, R. (2019). The potential for artificial intelligence in healthcare. Future healthcare journal, 6(2), 94-98.
[21] Secinaro, S., Calandra, D., Secinaro, A., Muthurangu, V., & Biancone, P. (2021). The role of artificial intelligence in healthcare: a structured literature review. BMC medical informatics and decision making, 21(1), 125.
[22] Jiang, F., Jiang, Y., Zhi, H., Dong, Y., Li, H., Ma, S., ... & Wang, Y. (2017). Artificial intelligence in healthcare: past, present and future. Stroke and vascular neurology, 2(4).
[23] Shortliffe, E. H., & Sepúlveda, M. J. (2018). Clinical decision support in the era of artificial intelligence. Jama, 320(21), 2199-2200.
[24] Kelly, C. J., Karthikesalingam, A., Suleyman, M., Corrado, G., & King, D. (2019). Key challenges for delivering clinical impact with artificial intelligence. BMC medicine, 17(1), 195.
[25] Panch, T., Szolovits, P., & Atun, R. (2018). Artificial intelligence, machine learning and health systems. Journal of global health, 8(2), 020303.
[26] Wiens, J., Saria, S., Sendak, M., Ghassemi, M., Liu, V. X., Doshi-Velez, F., ... & Goldenberg, A. (2019). Do no harm: a roadmap for responsible machine learning for health care. Nature medicine, 25(9), 1337-1340.
[27] Dey, D., Slomka, P. J., Leeson, P., Comaniciu, D., Shrestha, S., Sengupta, P. P., & Marwick, T. H. (2019). Artificial intelligence in cardiovascular imaging: JACC state-of-the-art review. Journal of the American College of Cardiology, 73(11), 1317-1335.
[28] Abràmoff, M. D., Lavin, P. T., Birch, M., Shah, N., & Folk, J. C. (2018). Pivotal trial of an autonomous AI-based diagnostic system for detection of diabetic retinopathy in primary care offices. NPJ digital medicine, 1(1), 39.
[29] Drummond, M. F., Sculpher, M. J., Claxton, K., Stoddart, G. L., & Torrance, G. W. (2015). Methods for the economic evaluation of health care programmes. Oxford university press.
[30] Neumann, P. J., Sanders, G. D., Russell, L. B., Siegel, J. E., & Ganiats, T. G. (Eds.). (2016). Cost-effectiveness in health and medicine. Oxford University Press.
